MaxCyte Inc - platform technologies provider for cell engineering - Submits a draft registration statement with the Securities & Exchange Commission relating to a proposed dual-listing and public offering on the Nasdaq Stock Market in New York. The company says the number of securities to be offered and their price has not yet been determined. The offering is expected to start after the comission completes its review process.
Current stock price: 902.50 pence, up 0.3% on Friday
Year-to-date change: up 71%
By Evelina Grecenko; evelinagrecenko@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
MaxCyte (MXCT)